Bilal Aziz, MD
Nephrology · Tahlequah, OKNPI 1063725901
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Vifor Pharma, Inc. accounts for 85.7% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $6,566 and has fallen 97.5% since, to $162 in 2023.
Across 82 payments — averaging $90.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vifor Pharma, Inc.$6K
- AstraZeneca$348
- Otsuka America Pharmaceutical, Inc.$231
- OPKO Pharmaceuticals, LLC$159
- Bayer$50
- GSK$49
- plus $223 from 8 others
What the payments were for
- Consulting fees$4,20057%
- Travel & lodging$1,63822%
- Food & beverage$1,49220%
- Education$961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vifor Pharma, Inc. | 19 | $6,365 |
| AstraZeneca(2 entities) | 23 | $348 |
| Otsuka America Pharmaceutical, Inc. | 12 | $231 |
| OPKO Pharmaceuticals, LLC | 9 | $159 |
| Bayer | 3 | $50 |
| GSK | 4 | $49 |
| Amicus Therapeutics, Inc. | 3 | $46 |
| Pharmacosmos Therapeutics Inc. | 1 | $44 |
| Amgen(2 entities) | 2 | $34 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $25 |
| Sanofi | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Akebia Therapeutics Inc | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veltassa$6,077
How this compares
$7,426 in reported general payments places this provider in the 80th percentile of 106 nephrology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 72 | $18,277 |
| ProsolParenteral Amino Acid 20% No.1 | 82 | $13,217 |
| Calcium Acetate | 51 | $5,222 |
| Midodrine Hcl | 12 | $824 |
| Furosemide | 79 | $723 |
| Hydralazine Hcl | 27 | $464 |
| Amlodipine Besylate | 59 | $354 |
| Losartan Potassium | 39 | $278 |
| Carvedilol | 43 | $234 |
| Metoprolol Succinate | 17 | $182 |
| Fluconazole | 22 | $142 |
| Potassium Chloride | 14 | $103 |
| Tamsulosin Hcl | 11 | $97 |
| Lisinopril | 15 | $59 |
| Clonidine Hcl | 19 | $54 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Tahlequah
- Celeste BoeckmanOklahoma City$90K
- Joseph GhataOklahoma City$45K
- Sunil AgrawalTulsa$40K
- Benjamin CowleyOklahoma City$36K
- Pranay KathuriaTulsa$21K
- Kevin FuTulsa$14K
- Diptesh GuptaTulsa$13K
- Brad CarterOklahoma City$13K
- Janet RussellTulsa$12K
- Bobby MuthalalyTulsa$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.